Share ownership Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/09/2024 BST			5-day change	1st Jan Change
22.22 ^USD	-4.43%		-6.76%	-27.39%

09-03	Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	MT
09-03	Transcript : Arrowhead Pharmaceuticals, Inc. - Shareholder/Analyst Call

Share class: Arrowhead Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	124,315,274	118,763,037 ( 95.53 %)	0	95.53 %

Major shareholders: Arrowhead Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 12.01 %	14,935,037	12.01 %	356 M $
Vanguard Fiduciary Trust Co. 9.825 %	12,214,101	9.825 %	291 M $
Avoro Capital Advisor LLC 7.150 %	8,888,888	7.150 %	212 M $
Fidelity Management & Research Co. LLC 5.480 %	6,812,233	5.480 %	162 M $
State Street Corp. 4.696 %	5,837,762	4.696 %	139 M $
Slate Path Capital LP 3.329 %	4,139,000	3.329 %	99 M $
Christopher Anzalone 2.988 %	3,715,048	2.988 %	89 M $
Artal Group SA 2.566 %	3,189,389	2.566 %	76 M $
Geode Capital Management LLC 2.363 %	2,937,948	2.363 %	70 M $
T. Rowe Price Investment Management, Inc. 2.060 %	2,560,833	2.060 %	61 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	65.06%
Other	8.69%
State Street Corp.	4.70%
Individuals	4.46%
Schweizerische Nationalbank	0.20%
Corebridge Financial, Inc.	0.18%
Silvercrest Asset Management Group, Inc.	0.12%
Manulife Financial Corp.	0.12%
Governments	0.08%
SEI Investments Co.	0.06%
Unknown	16.33%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	67.98%
Individuals	4.46%
Luxembourg	3.81%
United Kingdom	3.24%
Norway	1.29%
Switzerland	0.92%
Sweden	0.74%
Canada	0.35%
Netherlands	0.27%
China	0.12%
Denmark	0.11%
Ireland	0.08%
Australia	0.07%
Japan	0.05%
Israel	0.04%
Austria	0.04%
Germany	0.04%
France	0.03%

Based on 1000 largest holdings

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

525

Sector

Biotechnology & Medical Research

Calendar

24/09/2024 - R&D Webinar - Central Nervous System

Related indices

Russell 2000

More about the company